1,377 followers
.@jq1234t @PDRennert thx. CR 25%>12% w/ Revlimid. Promise in 50% of pts w/ DLBCL who relapse esp non-ASCT candidates http://t.co/A9SV6xrnTM
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Overview of attention for article published in Journal of Clinical Oncology, July 2008
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (96th percentile)
-
High Attention Score compared to outputs of the same age and source (87th percentile)
Mentioned by
- news
- 1 news outlet
- policy
- 1 policy source
- 1 X user
- patent
- 12 patents
- f1000
- 1 research highlight platform
- guideline
- 2 clinical guideline sources
Readers on
- mendeley
- 159 Mendeley
- citeulike
- 3 CiteULike